Californian drugmaker Gilead Sciences (Nasdaq: GILD) has exceeded estimates in the third quarter, with revenues of around $7.1 billion and earnings per share (EPS) of $1.73.
While the sales figure is similar to where it was in the same period of last year, profits were higher, up from about $1.42 per share in the third period of 2022, following generally accepted accounting principles (GAAP).
The strong showing was primarily driven by increased sales in oncology and HIV, offset by lower revenues for the firm’s COVID-19 antiviral Veklury (remdesivir).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze